Reviews in Urology Volume 23, Issue 3 2024Correction

Corrected drug delivery informationRev Urol. 2024;23(3):e25.In the bladder cancer review article titled “Management of Adverse Events From Checkpoint Inhibitors in Urologic Practice: Where Are We Today?” published July 8, 2024, in Reviews in Urology,¹ the text was updated to specify that the drug under discussion, sasanlimab, is delivered by subcutaneous injection. This article was corrected online and is available at https://journals.specialtynetworks.com/issues/vol/23/no/2/management-adverse-events-checkpoint-inhibitors-urologic-practice-today.References

Branch C, Canter D, Jayram G. Management of adverse events from checkpoint inhibitors in urologic practice: where are we today? Rev Urol. 2024;23(2):e41-e45.

CoverKEYTRUDAKEYTRUDA 2KEYTRUDA 3KEYTRUDA 4KEYTRUDA 5KEYTRUDA 6KEYTRUDA 7LUGPAJELMYTOJELMYTO 2Pfizer OncologyPfizer Oncology 2Leadership & Editorial StaffContentsLUGPA 2025Letter From the President of LUGPAPARP Resource GuideLUGPA NewsCorrectionIsoPSAAdvances in Radical Prostatectomy: A Narrative ReviewDarolutamide for the Management of Metastatic Hormone- Sensitive Prostate Cancer: A Urologist-Oncologist PerspectiveRecent Advances in Managing Pediatric Neurogenic Bladder due to Spina BifidaIncorporation of IsoPSA Into Clinical Practice in the Management of Elevated Prostate- Specific Antigen Based on Current GuidelinesResponse to Targeted Therapy and Checkpoint Inhibition in a Patient With Mucinous Tubular and Spindle Cell Carcinoma: A Case Report and Literature ReviewCiplaImmune Checkpoint Inhibitors for the Treatment of Non–Muscle-Invasive Bladder Cancer: An Overview of Ongoing Clinical TrialsThe Business of Independent Urologic Medicine: Caring for Patients While Operating a Business in a Post–COVID-19 Era of Private PracticeThe Specialty Networks Localized to High- Risk Biochemically Recurrent Prostate Cancer Patient PlaybookLocalized to High-Risk/Biochemically Recurrent Prostate CancerMeet the Expert: Shelby Moneer, MS, CHES, from ZERO Prostate CancerPPS AnalyticsWELIREGWELIREG 2WELIREG 3WELIREG 4WELIREG 5WELIREG 6Pfizer Urology Oncology